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S334 Poster Session IIand mortality. In our institution, 734 patients received an UCBT
between 2000 and 2010. The focus of this study was 76 patients
(10.4%) who had primary (n 5 55) or secondary (n 5 21) GF. Pri-
mary GF was defined as failure to achieve an absolute neutrophil
count (ANC) $ 500/mcL for 3 consecutive by day +42 or chime-
rism \5% in all assessments after transplantation regardless of
ANC. Secondary GF was defined as loss of chimerism\5% after
having achieved 5% or more after UCBT, or ANC persistently be-
low 500/mcL after having achieved $ 500/mcL for 3 consecutive
days by day +42. Patients were grouped as those with malignant
disease/myeloablative conditioning (MA, n 5 28), malignant
disease/nonmyeloablative conditioning (NMA, n 5 26) and non-
malignant disease (non-Malig, n 5 22). The OS at 100 days for pa-
tients with primary GF was 49%(95%CI, 35-61%) and secondary
GF was 76%(95%CI, 52-89%) (p 5 0.03). Thirty-nine patients un-
derwent a second transplant at a median time of 50 days (range:
32-565). Excluding patients with slow primary engraftment (n 5
10), who were counted as primary GF, the remaining 27 patients
were considered too ill to withstand a second transplant. Second
transplant conditioning included: no additional conditioning (n 5
10), ATG/ALG 6 steroids (n 5 11), and chemotherapy 6
ATG/ALG (n 5 18). Cumulative incidence of engraftment after
2nd transplant was 77% at a median time of 16 days (range:
0-39). Engraftment was similar in all groups. After 2nd transplant,
OS was 69%(95%CI, 52-81%) at 100 days and 41%(95%CI,
26-56%) at 1 year. The day 100 survival was 32%(95%CI,
16-49%) for MA, 73%(95%CI, 52-86%) for NMA and
68%(95%CI, 45-83%) for non-Malig patients(p 5 0.01). In evalu-
ation of time to second transplant, the OS at 100 days was similar
for patients transplanted # 50 or . 50 days: (62%[95%CI,
38-79%] vs. 78% [95%CI, 51-91%] respectively, p 5 0.31); there
was also no difference in OS at 1 year (33%[95%CI, 15-53%] vs.
50%[95%CI, 26-70%] respectively, p 5 0.34). The most frequent
causes of death at day 100 after 2nd transplant were: second graft
failure, bacterial infection and disease recurrence. In conclusion,
patients with primary or secondary GF after UCBT who undergo
a second transplant have encouraging survival with over 40% sur-
viving 1 year, and identifying strategies to overcome graft failure
will help to improve upon this.Table 1. Demographic data of MDS patients underwent allo-
geneic HCT
N 5 79
Median Age at diagnosis, years (Range) 49.7 (19-65)
Median Age at transplant, years (Range) 51.0 (20-66)
Gender, M/F 43/36
IPSS#
High 17 (21.5%)
High Intermediate 40 (50.6%)
Low Intermediate 18 (22.8%)
Low 4 (5.1%)
Disease status at transplant
Complete remission 10 (12.7%)
Residual or active hematologic disease 69 (87.3%)
HCT-CI
0 22 (27.8%)
1-2 15 (20.0%)
$3 42 (52.2%)
HLA compatability
6/6 or 8/8 65 (72.3%)
4/6, 5/6 or 7/8 14 (27.7%)
Donor
Related 39 (49.4%)
Unrelated 40 (5.6%)
IPSS Cytogenetic classification
Favorable 26 (32.9%)
Intermediate 16 (20.2%)
Unfavorable* 37 (46.8%)
Monosomal karyotype 24 (30.4%)
#Internation Prognostic Scoring System.
*Unfavorable karyotypes include complex cytogenetic abnormality ($3
structural abnormalities) or abnormal chromosome 7.350
EXPRESSION OF a4b7 INTEGRIN ON PERIPHERAL BLOOD MEMORY
CD4+ T-CELLS AFTER ALLOGENEIC HCT CORRELATES WITH NON-
RELAPSE MORTALITY AND OVERALL SURVIVAL
Y.-B., Chen1, McDonough, S.2, Chen, H.3, Kennedy, J.1, Alyea, E.P.2,
Armand, P.2, Ballen, K.K.1, Cutler, C.2, Dey, B.R.1, Ho, V.T.2,
Koreth, J.2, McAfee, S.L.1, Spitzer, T.R.1, Antin, J.H.2, Soiffer, R.J.2,
Jagasia, M.3, Ritz, J.2 1Massachusetts General Hospital, Boston, MA;
2Dana-Farber Cancer Institute, Boston, MA; 3Vanderbilt University,
Nashville, TN
Background: Surface expression of a4b7 integrin, a gut-homing
lymphocyte trafficking molecule, on peripheral blood memory T-
cells has been shown to be increased in patients who develop acute
intestinal graft-vs.-host disease (GVHD) after allogeneic hemato-
poietic cell transplantation (HCT).Decreased expression of a4b7 in-
tegrin on regulatory T-cells at engraftment has also been shown to
correlate with the development of intestinal GVHD. We hypothe-
sized that a4b7 integrin expressingmemory T-cells in the peripheral
blood at day +15 and day +30 after HCT would be associated with
the development of acute intestinal GVHD and survival outcomes.
Methods: Serial samples at day +15 and day +30 from 84 patients un-
dergoing either RIC or myeloablative conditioning allogeneic HCT
with peripheral blood stem cells were analyzed. Median follow-up
was 661 days (range 39, 907 days) among survivors. T-cell subsets
chosen for analysis included na€ıve and memory (defined by expres-
sion of CD45RA and CD45RO, respectively) CD4+ and CD8+ T-
cells. Expression of a4b7 integrin was assessed by flow cytometry.
Results: Increased percentage of memory CD4+ T-cells expressing
a4b7 integrin at day +15 correlated with increased non-relapse
mortality (NRM) (p 5 0.005) and decreased overall survival (OS)
(p 5 0.016). The cumulative incidence of NRM was 25% (21 /
84) (95% CI 16%, 34%) in this cohort. Expression on any na€ıve
T-cell subset, on memory CD8+ T-cells, or at day +30 was notshown to correlate with outcomes. Further analysis showed that
conditioning intensity, donor type, GVHD prophylaxis regimen,
use of in vivo T-cell depletion, and underlying disease had no sig-
nificant effect on the % of memory CD4+ T-cells expressing a4b7
integrin. Expression of a4b7 integrin on any T-cell subset did not
correlate with the development of acute intestinal GVHD, al-
though there were only 5 cases of grade II and 7 cases of grades
III-IV disease in this cohort.
Conclusion: Expression of a4b7 integrin on memory CD4+ T-cells
at day +15 after HCT predicts for NRM and OS. Analysis with
a larger number of samples is planned to confirm these results, but
continued study of a4b7 integrin as a biomarker or target of inter-
vention after HCT is warranted. This biomarker may be valuable
in identifying a high risk subset of patients who could benefit from
pre-emptive organ specific targeted intervention.
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OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN MYELODYS-
PLASTIC SYNDROMES WITH MONOSOMAL KARYOTYPE: AN ADVERSE
PROGNOSTIC FACTOR IN ADDITION TO CONVENTIONAL UNFAVORABLE
KARYOTYPE
Wudhikarn, K.1, Van Rheeden, R.2, Leopold, C.3, Rattanaumpawan, P.4,
Gingrich, R.D.1, Silverman, M.1 1University of Iowa Hospital and Clinic,
Iowa City, IA; 2University of Iowa Hospital and Clinic, Iowa City, IA;
3University of Iowa Hospital and Clinics, Iowa City, IA; 4University of
Pennsylvania School of Medicine, Philadelphia, PA
Introduction: Monosomal karyotype (MK) is defined as the pres-
ence of two or more distinct autosomal monosomies or a single
monosomy associated with a structural abnormality. It was first de-
scribed as an adverse prognosis for acute myeloblastic leukemia. Re-
cently, Patnaik et al demonstrated adverse prognostic effect ofMK in
myelodysplastic syndromes (MDS). However, the effect of MK on
the allotransplant in MDS is not yet well described.
Methods: MDS patients who underwent allotransplant at the Uni-
versity of Iowa from 1990 to 2009 were retrospectively reviewed. Cy-
togenetic and patient’s data were abstracted from medical genetics
and transplant database. Patients were classified according to
Poster Session II S335cytogenetic abnormalities (favorable, intermediate or unfavorable
risk group) based on International Prognostic Scoring System
(IPSS). We evaluated allotransplant outcome in MDS patients
with MK.
Result: A total of 79 MDS patients who underwent allotransplant
were identified. Thirty seven of 79 patients (46.8%) harbored unfa-
vorable karyotypes (23 complex karyotype, 25 abnormal chromo-
some 7). Of 79 patients, 24 (30%) met the criteria of MK. The
median follow-up was 5.1 months (0-242 mo). Twenty-four patients
(30%) relapsed and 59 (74.7%) died during the follow-up duration.
Major causes of death included infection (24%), graft versus host dis-
ease (25%) and relapse (31%). Two-year relapse incidence (RI) and
overall survival (OS) were 36% (95%CI, 23%-49%) and 32% (95%
CI, 22%-43%) respectively. Of 79 patients, patients with MK had
significantly higher 2-year RI (51% VS 28%; p 5 0.01) (95%CI,
28-75% VS 13-43%) and lower 2-year OS (6% VS 41%; p 5 0.02)
(95%CI, 0-24%VS 28-54%) than patients without MK. Due to sig-
nificant overlap betweenMK and unfavorable karyotypes, we further
analyzed the effect of MK in each unfavorable karyotype composite
(unfavorable with MK VS unfavorable without MK). Although the
outcome was not statistically different, patients with both unfavor-
able karyotype and MK had a trend toward higher 2-year RI (51%
VS 38%, hazaard ratio [HR] 1.7, p 5 0.34) and lower 2-year OS
(6%VS 31%,HR 1.5, p5 0.28) compare with patients with unfavor-
able karyotypes without MK.
Conclusion: MK is associated with poor allotransplant outcome
with high relapse incidence and low overall survival in addition to
IPSS unfavorable cytogenetic abnormalities.352
MELPHALAN 140MG/M2 COMBINED WITH TBI2(4)Gy AND FLUDARA-
BINE 125MG/M2 AS CONDITIONING FOR ELDERLY PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES IN UNRELATED BONE MARROW
TRANSPLANTATION IS COMPARABLE IN SAFETY AND EFFECTIVENESS
WITH TBI/CY FOR YOUNGER PATIENTS
Ueki, T., Sato, K., Fujikawa, Y., Shimizu, I., Akahane, D., Sumi, M.,
Ueno, M., Ichikawa, N., Kobayashi, H. Nagano Redcross Hospital,
Nagano, Japan
Background:The optimal conditioning and dosage regimen for un-
related bone marrow transplantation for elderly patients with hema-
tological malignancies remains unknown.
Objective and Methods: Among the 63 cases of unrelated bone
marrow transplantation for hematological malignancies performed
in our department, we compared and examined the safety and effi-
cacy of the most commonly used conditioning regimen for elderly
patients, i.e., fludarabine (Flu) (125mg/m2) + melphalan (Mel)
(140mg/m2) + total body irradiation (TBI) [2(4)Gy] (22 cases; here-
after Flu/Mel/TBI group), with theTBI (12Gy) + cyclophosphamide
(CY) (120mg/kg) regimen (23 cases; hereafter TBI/CY group). For 3
cases in the Flu/Mel/TBI group, TBI was increased to 4Gy from
2Gy due to myelodysplastic syndrome associated with each of mye-
lofibrosis, splenomegaly, and aplastic anemia.
Results: The mean age of patients was 58.5 years (range, 40-66
years) for the Flu/Mel/TBI group and 40 years (range, 21-57 years)
for the TBI/Cy group, with the Flu/Mel/TBI group being signifi-
cantly older (p5 0.002). Acute lymphoblastic leukemia was common
in the TBI/CY group. The number of high risk cases did not signif-
icantly differ between the two groups (Flu/Mel/TBI group, 50%;
TBI/CY group, 30%). There were no differences in the number of
days required for engraftment or to achieve complete donor chime-
rism. Early adverse events higher than grade 3, and bacterial, fungal,
or viral infections within one year were 72.7%, 45.5%, 18.2%, and
45.5% in the Flu/Mel/TBI group, and 73.9%, 26.1%, 17.4%, and
52.2% in the TBI/CY group, with no significant difference between
the groups. Acute and chronic GVHD were observed in 56.5% and
81%of cases in the Flu/Mel/TBI group, and 52.5% and 53.4% in the
TBI/CY group, with the Flu/Mel/TBI group having a significantly
higher incidence of chronic GVHD (p5 0.014). The median obser-
vation period of survivors was 30months for the Flu/Mel/TBI group
and 68 months for the TBI/CY group. Two year overall survival and
relapse-free survival were 72.4% and 59.1% in the Flu/Mel/TBI
group, and 77.5% and 64.1% in the TBI/CY group; and two year
treatment-related mortality and recurrence rate were 14.6% and30.8% in the Flu/Mel/TBI group, and 0% and 35.9% in the TBI/
CY group, with no significant differences between the groups.
Conclusion: Flu/Mel/TBI for elderly individuals with hematologi-
cal malignancies proved to be as effective and safe as TBI/CY for
younger patients.
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A PROSPECTIVE RANDOMIZED STUDY COMPARING REDUCED-INTEN-
SITY CONDITIONING AND MYELOABLATIVE CONDITIONING IN PA-
TIENTS WITH MYELOID LEUKEMIA UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ringden, O.1, Erkers, T.1, Aschan, J.2, Le Blanc, K.3, Hagglund, H.4,
Omazic, B.1, Svenberg, P.1, Ljungman, P.4, Mattsson, J.1,
Remberger, M.1 1Karolinska Institutet, Stockholm, Sweden; 2Karolinska
University Hospital Huddinge, Stockholm, Sweden; 3Karolinska Institu-
tet, Stockholm, Sweden; 4Karolinska University Hospital Huddinge,
Stockholm, Sweden
There have been no randomized studies comparing myeloablative
conditioning (MAC) and reduced-intensity conditioning (RIC) in al-
logeneic hematopoietic stem cell transplantation (HSCT). We
wanted to compare the safety and efficacy of these two regimens.
We performed an open-labeled, randomized, controlled phase-III
trial. Over a 10-year period, adult patients#60 years of age with my-
eloid leukemia were randomised (1:1) to undergo RIC (n 5 18) or
MAC (n 5 19). We included recipients of HLA-A, HLA-B, or
HLA-DRB1-identical unmanipulated grafts from related or unre-
lated donors. The primary endpoint was transplant-relatedmortality
(TRM). Secondary endpoints included relapse, survival, chimerism,
and toxicity.
The RIC patients had faster platelet engraftment (p\0.01), re-
quired fewer erythrocyte and platelet transfusions (p\0.001), and re-
quired less total parenteral nutrition (TPN) than the MAC group
(p\0.01). Cytomegalovirus reactivation was commoner in the
MAC group (14/19) than in the RIC group (6/18) (p5 0.02). Hem-
orrhagic cystitis occurred in eight of the MAC patients and in none
of the RIC patients (p\0.01). Donor chimerism was similar in the
two groups regarding CD19 and CD33, but was delayed for CD3
in the RIC group. Later chimerism status was similar. Incidences
of acute and chronic graft-versus-host disease (GVHD) were similar
in the two groups, but twoMACpatients and no RIC patients died of
GVHD. Five-year TRM was around 11% in both groups, and re-
lapse and survival were not significantly different. TheMACpatients
with intermediate cytogenetic acute myeloid leukemia had a three-
year survival of 73%, as compared to 90% in the RIC patients.
TRMwas lowwith RIC andMAC. Although few patients were in-
cluded, RIC had several advantages such as faster platelet engraft-
ment, fewer transfusions, less TPN, fewer CMV reactivations, and
less hemorrhagic cystitis.
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OUTCOME OF HIGH-RISK AND REFRACTORY AML/MDS PATIENTS RE-
CEIVING A FLAMSA SEQUENTIAL CHEMOTHERAPY REGIMEN FOLLOWED
BY REDUCED-INTENSITY CONDITIONING (RIC) AND ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANTATION (allo-HSCT)
Detrait, M.1, Chevallier, P.2, Sobh, M.1, Guillaume, T.2, Thomas, X.1,
Morisset, S.1, Tedone, N.1, Delaunay, J.2, Nicolini, F.1, Ducastelle, S.1,
Chelghoum, Y.1, Barraco, F.1, Labussiere, H.1, Mohty, M.2,
Michallet, M.1 1Centre Hospitalier Lyon Sud, Pierre Benite, France; 2Ho-
tel Dieu Hospital, University of Nantes, Nantes, France
This retrospective analysis aimed to assess the outcome of 40 pa-
tients with refractory or high risk AML/MDS who received
FLAMSA sequential chemotherapy. There were 30 males and 10 fe-
males with a median age of 52 years (32-66). Diseases characteristics
were: progressive or refractory disease after rescue treatment for first
relapse (n 5 21), early relapse without any further salvage therapy
(n 5 4), and primary induction failure (n 5 4). The series also in-
cluded 7 patients with high risk MDS and 4 patients in first CR
but having a very poor prognosis. The FLAMSA regimen included
Fludarabine (30 mg/m2/d), cytarabine (2 g/m2/d) and amsacrine
(100mg/m2/d) from day -12 to day -9. After 3 days of rest, a RIC reg-
imen was administered. In 28 patients, the RIC regimen included 4
